Dataset Information


Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

ABSTRACT: Recombinant tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an antitumor protein that is in clinical trials as a potential anticancer therapy but suffers from drug properties that may limit efficacy such as short serum half-life, stability, cost, and biodistribution, particularly with respect to the brain. To overcome such limitations, we identified TRAIL-inducing compound 10 (TIC10), a potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier. TIC10 induces a sustained up-regulation of TRAIL in tumors and normal cells that may contribute to the demonstrable antitumor activity of TIC10. TIC10 inactivates kinases Akt and extracellular signal-regulated kinase (ERK), leading to the translocation of Foxo3a into the nucleus, where it binds to the TRAIL promoter to up-regulate gene transcription. TIC10 is an efficacious antitumor therapeutic agent that acts on tumor cells and their microenvironment to enhance the concentrations of the endogenous tumor suppressor TRAIL.


PROVIDER: S-EPMC4535715 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4537643 | BioStudies
2019-01-01 | S-EPMC6620139 | BioStudies
2013-01-01 | S-EPMC3729926 | BioStudies
2010-01-01 | S-EPMC2862835 | BioStudies
2003-01-01 | S-EPMC164479 | BioStudies
2018-01-01 | S-EPMC6185741 | BioStudies
2020-01-01 | S-EPMC7156767 | BioStudies
2015-01-01 | S-EPMC4541796 | BioStudies
1000-01-01 | S-EPMC4742189 | BioStudies
2019-01-01 | S-EPMC6461257 | BioStudies